AFT appoints Andrew Lane as independent director

28 September 2023
AFT appoints Andrew Lane as independent director
AFT Pharmaceuticals (NZX; AFT, ASX; AFP) today announces the appointment of Andrew Lane as an independent non-executive director.
The appointment fills the vacancy left by Jon Lamb who retires from the board today following his 11-year tenure.
Chair David Flacks says: “We are delighted to welcome Andrew to our board. He has outstanding experience as a senior business executive in international growth markets, having most recently led Abbott Laboratories Pharmaceutical Division with turnover growing from NZ$4 Bil to over NZ$9 Bil during his tenure.
“This unique experience is highly relevant to AFT as we grow and consolidate our position in Australasia and build our presence internationally with our Maxigesic® pain relief and other medications.”
Andrew says: “I am excited by the opportunity to assist AFT with its growth aspirations and will be using my accumulated knowledge in finance, sales and marketing within general, regional and global management for this.”
The board has determined that Andrew Lane is an Independent Director (within the meaning of the NZX Listing Rules).

For and on behalf of AFT Pharmaceuticals Limited by Malcolm Tubby, Chief Financial Officer.

For more information:
Investors Media
Dr Hartley Atkinson Richard Inder
Managing Director The Project
AFT Pharmaceuticals Tel: +64 21 645 643
Tel: +64 9488 0232

About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.

---

Announcement PDF